Download Data Supplement for “Circulating Cancer Cells and their Clinical

Data Supplement for “Circulating Cancer Cells and their Clinical Applications”
Clinical Chemistry Q&A prepared by Dr. Eleftherios P. Diamandis
Suggested reading:
1)
Pantel K, Alix-Panabières C. “Circulating tumour cells in cancer patients:
challenges and perspectives” Trends Mol Med. 2010;16:398-406
2)
Pantel K, Riethdorf S. “Pathology: are circulating tumor cells predictive of
overall survival?” Nat Rev Clin Oncol. 2009;6:190-1
3)
Pantel K, Brakenhoff RH, Brandt B. “Detection, clinical relevance and
specific biological properties of disseminating tumour cells” Nat Rev Cancer.
2008;8:329-40
4)
Cristofanilli M, Budd GT, Ellis MJ, et al. “Circulating tumor cells, disease
progression, and survival in metastatic breast cancer” N Engl J Med.
2004;351:781-91
5)
Riethdorf S, Fritsche H, Müller V, et al. “Detection of circulating tumor cells
in peripheral blood of patients with metastatic breast cancer: a validation
study of the CellSearch system” Clin Cancer Res. 2007;13:920-8
6)
Steele NL, Plumb JA, Vidal L, et al “A phase 1 pharmacokinetic and
pharmacodynamic study of the histone deacetylase inhibitor belinostat in
patients with advanced solid tumors” Clin Cancer Res. 2008;14:804-10.
7)
Cohen SJ, Punt CJ, Iannotti N, et al “Relationship of circulating tumor cells to
tumor response, progression-free survival, and overall survival in patients
with metastatic colorectal cancer” J Clin Oncol. 2008;26:3213-21
8)
Lin HK, Zheng S, Williams AJ, et al. “Portable filter-based microdevice for
detection and characterization of circulating tumor cells” Clin Cancer Res.
2010;16:5011-8
9)
Fehm T, Solomayer EF, Meng S, et al. “Methods for isolating circulating
epithelial cells and criteria for their classification as carcinoma cells”
Cytotherapy. 2005;7:171-85.
10)
Stott SL, Hsu CH, Tsukrov DI, et al. “Isolation of circulating tumor cells
using a microvortex-generating herringbone-chip” Proc Natl Acad Sci.
2010;107:18392-7
11)
Nagrath S, Sequist LV, Maheswaran S et al. “Isolation of rare circulating
tumour cells in cancer patients by microchip technology” Nature.
2007;450:1235-9
12)
Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. “Molecular
characterization of circulating tumor cells in breast cancer by a liquid bead
array hybridization assay” Clin Chem. 2011;57:421-30
13)
Stathopoulou A, Ntoulia M, Perraki M, et al. “A highly specific real-time RTPCR method for the quantitative determination of CK-19 mRNA positive cells
in peripheral blood of patients with operable breast cancer” Int J Cancer.
2006;119:1654-9
14)
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. “Stem
cell and epithelial-mesenchymal transition markers are frequently
overexpressed in circulating tumor cells of metastatic breast cancer patients”
Breast Cancer Res. 2009;11:R46.
15)
Alix-Panabières C, Vendrell JP, Slijper M, et al. “Full-length cytokeratin-19 is
released by human tumor cells: a potential role in metastatic progression of
breast cancer” Breast Cancer Res. 2009;11:R39
16)
Fehm T, Braun S, Muller V, et al. “A concept for the standardized detection of
disseminated tumor cells in bone marrow from patients with primary breast
cancer and its clinical implementation” Cancer. 2006;107:885-92.
17)
Riethdorf S, Müller V, Zhang L, et al. “Detection and HER2 expression of
circulating tumor cells: prospective monitoring in breast cancer patients
treated in the neoadjuvant GeparQuattro trial” Clin Cancer Res.
2010;16:2634-45
18)
Kraan J, Sleijfer S, Strijbos MH, et al. “External quality assurance of
circulating tumor cell enumeration using the CellSearch(®) system: A
feasibility study” Cytometry B Clin Cytom. 2011;80:112-8
19)
Bustin SA, Benes V, Garson JA, et al. “The MIQE guidelines: minimum
information for publication of quantitative real-time PCR experiments” Clin
Chem. 2009;55:611-22
20)
Becker S, Becker-Pergola G, Banys M, et al. “Evaluation of a RT-PCR based
routine screening tool for the detection of disseminated epithelial cells in the
bone marrow of breast cancer patients” Breast Cancer Res Treat.
2009;117:227-33
21)
Fehm T, Müller V, Aktas B, et al. “HER2 status of circulating tumor cells in
patients with metastatic breast cancer: a prospective, multicenter trial” Breast
Cancer Res Treat. 2010;124:403-12
22)
Braun S, Pantel K, Müller P, et al. “Cytokeratin-positive cells in the bone
marrow and survival of patients with stage I, II, or III breast cancer” N Engl J
Med. 2000;342:525-33
23)
Braun S, Vogl FD, Naume B, et al. “A pooled analysis of bone marrow
micrometastasis in breast cancer” N Engl J Med. 2005;353:793-802
24)
Attard G, Swennenhuis JF, Olmos D, et al “Characterization of ERG, AR and
PTEN gene status in circulating tumor cells from patients with castrationresistant prostate cancer” Cancer Res. 2009;69:2912-8
25)
Danila DC, Morris MJ, de Bono JS, et al. “Phase II multicenter study of
abiraterone acetate plus prednisone therapy in patients with docetaxel-treated
castration-resistant prostate cancer” J Clin Oncol. 2010;28:1496-501.
26)
Xenidis N, Perraki M, Kafousi M, et al. “Predictive and prognostic value of
peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time
polymerase chain reaction in node-negative breast cancer patients” J Clin
Oncol. 2006;24:3756-62
27)
Ignatiadis M, Kallergi G, Ntoulia M, et al. “Prognostic value of the molecular
detection of circulating tumor cells using a multimarker reverse transcriptionPCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast
cancer” Clin Cancer Res. 20081;14:2593-600
28)
Xenidis N, Ignatiadis M, Apostolaki S, et al. “Cytokeratin-19 mRNA-positive
circulating tumor cells after adjuvant chemotherapy in patients with early
breast cancer” J Clin Oncol. 2009;27:2177-84
29)
Meng S, Tripathy D, Shete S, et al “HER-2 gene amplification can be
acquired as breast cancer progresses” Proc Natl Acad Sci U S A.
2004;101:9393-8.
30)
Kallergi G, Markomanolaki H, Giannoukaraki V, et al. “Hypoxia-inducible
factor-1alpha and vascular endothelial growth factor expression in circulating
tumor cells of breast cancer patients” Breast Cancer Res. 2009;11:R84.
31)
Bozionellou V, Mavroudis D, Perraki M, et al. “Trastuzumab administration
can effectively target chemotherapy-resistant cytokeratin-19 messenger RNApositive tumor cells in the peripheral blood and bone marrow of patients with
breast cancer” Clin Cancer Res. 2004;10:8185-94.
32)
Tejada ML, Yu L, Dong J, et al “Tumor-driven paracrine platelet-derived
growth factor receptor alpha signaling is a key determinant of stromal cell
recruitment in a model of human lung carcinoma” Clin Cancer Res.
2006;12:2676-88
33)
Ignatiadis M, Xenidis N, Perraki M, et al. “Different prognostic value of
cytokeratin-19 mRNA positive circulating tumor cells according to estrogen
receptor and HER2 status in early-stage breast cancer” J Clin Oncol. 2007
Nov 20;25(33):5194-202
34)
Yen LC, Yeh YS, Chen CW, et al “Detection of KRAS oncogene in
peripheral blood as a predictor of the response to cetuximab plus
chemotherapy in patients with metastatic colorectal cancer” Clin Cancer Res.
2009;15:4508-13
35)
Maheswaran S, Sequist LV, Nagrath S, et al. “Detection of mutations in
EGFR in circulating lung-cancer cells” N Engl J Med. 2008;359:366-77
36)
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H,
Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells
predict survival benefit from treatment in metastatic castration-resistant
prostate cancer. Clin Cancer Res. 2008;14:6302-9. Erratum in: Clin Cancer
Res. 2009;15:1506.
37)
Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G.
Circulating tumour cells as prognostic markers in progressive, castrationresistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol.
2009;10:233-9.